Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Relenza
Zanamivir, marketed under the brand name Relenza, is an antiviral medication used to treat and prevent influenza A and B virus infections. It belongs to a class of drugs called neuraminidase inhibitors, which work by blocking the neuraminidase enzyme on the surface of the virus. This prevents the virus from releasing itself from infected cells and spreading to other cells in the body. Zanamivir is typically administered via inhalation using a specifically designed device called a Diskhaler.
For the treatment and prevention of influenza A and B virus infections.
Outcome:
Reduced effectiveness of LAIV
Mechanism:
Zanamivir may interfere with the replication of the live attenuated virus in LAIV.
Outcome:
Increased risk of bleeding
Mechanism:
Both drugs inhibit platelet function.
Outcome:
Reduced absorption of zanamivir
Mechanism:
Chelation of drug in GI tract
Most likely new formulation: Long-acting injectable zanamivir (Year: 2026, 70% confidence)
Based on current usage trends and emerging resistance patterns, there is a 15% likelihood of increased restrictions on zanamivir use within the next 5 years.
Antiviral, Neuraminidase Inhibitor
Sialic Acid Analogue